» Articles » PMID: 35456269

Perception of the Regulatory Change for Zolpidem Prescription by French General Practitioners and Its Relation to Prescription Behavior

Overview
Journal J Clin Med
Specialty General Medicine
Date 2022 Apr 23
PMID 35456269
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To “limit the risk of abuse and misuse” and “encourage correct usage”, the French drug regulatory authority stated that—from April 2017—zolpidem prescription must be performed on a secured prescription pad. This national study aims to evaluate the perception of general practitioners (GPs) towards this new regulation and its link with prescription strategies. Methods: We conducted structured interviews of GPs. Data were collected about GPs’ perception of the measure and therapeutic strategies towards zolpidem. The primary outcome was the description of the GPs’ strategy of prescription, based on the perception towards the new regulation for zolpidem. Results: For 206 GPs, the new regulation was mainly perceived as helpful (61%) and as a difficulty (55%). Other perceptions were the awareness of the risks of zolpidem (18%), awareness of the risks of hypnotics (13%), and nothing changed (5%). Four clusters of GPs were identified. In the clusters with the perception as a difficulty (only or associated with helpful), the GPs who applied the strategy “no modification” for >50% of their patients were more frequently compared to awareness and helpful only clusters (60.8%; 42.9%; 20.4%; 26.7%) (p < 0.001). Conclusions: We highlighted an association between the perception of the new regulation of zolpidem prescription by GPs and a strategy of prescription.

Citing Articles

Dispensing of zolpidem and benzodiazepines in Brazilian private pharmacies: a retrospective cohort study from 2014 to 2021.

Carvalho F, Tonon A, Hidalgo M, Costa M, Mengue S Front Pharmacol. 2024; 15:1405838.

PMID: 39588152 PMC: 11586159. DOI: 10.3389/fphar.2024.1405838.


The effect of education regarding treatment guidelines for schizophrenia and major depressive disorders on psychiatrists' hypnotic medication prescribing behavior: a multicenter study.

Nakamura T, Furihata R, Hasegawa N, Kodaka F, Muraoka H, Ichihashi K BMC Psychiatry. 2024; 24(1):399.

PMID: 38807065 PMC: 11135008. DOI: 10.1186/s12888-024-05816-x.


Prescribing Z-drugs in Greece: an analysis of the national prescription database from 2018 to 2021.

Siafis S, Fountoulakis K, Fragkidis V, Papazisis G BMC Psychiatry. 2023; 23(1):370.

PMID: 37237252 PMC: 10214344. DOI: 10.1186/s12888-023-04793-x.


Did the New French Regulation of Zolpidem Decrease the Problematic Consumption of Zolpidem? A Field Study among Users.

Laforgue E, Rousselet M, Claudon A, Aquizerate A, Jolliet P, Istvan M Int J Environ Res Public Health. 2022; 19(15).

PMID: 35897285 PMC: 9331950. DOI: 10.3390/ijerph19158920.

References
1.
Bogunovic O, Greenfield S . Practical geriatrics: Use of benzodiazepines among elderly patients. Psychiatr Serv. 2004; 55(3):233-5. DOI: 10.1176/appi.ps.55.3.233. View

2.
Siriwardena A, Qureshi Z, Gibson S, Collier S, Latham M . GPs' attitudes to benzodiazepine and 'Z-drug' prescribing: a barrier to implementation of evidence and guidance on hypnotics. Br J Gen Pract. 2006; 56(533):964-7. PMC: 1934058. View

3.
Jouanjus E, Guernec G, Lapeyre-Mestre M . Medical prescriptions falsified by the patients: a 12-year national monitoring to assess prescription drug diversion. Fundam Clin Pharmacol. 2018; 32(3):306-322. DOI: 10.1111/fcp.12356. View

4.
Rousselet M, Feuillet F, Gerardin M, Jolliet P, Hardouin J, Victorri-Vigneau C . The French addictovigilance network clinical assessment: Z-drugs, true false twins. Expert Opin Drug Saf. 2017; 16(9):1063-1069. DOI: 10.1080/14740338.2017.1346084. View

5.
Bjorvatn B, Meland E, Flo E, Mildestvedt T . High prevalence of insomnia and hypnotic use in patients visiting their general practitioner. Fam Pract. 2016; 34(1):20-24. DOI: 10.1093/fampra/cmw107. View